Business 2 min read By Alice Ashford
Chugai expects full-year profit to beat forecast on drug exports
Japanese drugmaker Chugai Pharmaceutical says its full-year results will exceed its earlier forecast, driven by growing drug exports and royalty income.
Chugai Pharmaceutical, the Japanese drugmaker that is part of the Roche group, expects its full-year results to exceed its previous forecast. The company says stronger overseas sales of its medicines and rising royalty income are the main drivers behind the improved outlook.
The expected outperformance reflects demand for Chugai's products outside Japan, where exports have grown as partners have expanded their commercial activity. Royalty payments linked to licensed products have also added to revenue, giving the company a broader income base than domestic sales alone would provide.
For investors, the update signals that the Tokyo-listed group is performing ahead of the targets it set earlier in the financial year. Companies in the pharmaceutical sector often revise guidance as currency movements, pricing and licensing arrangements shift, and Chugai's upgrade points to resilience in its export business at a time when the wider sector faces pressure on drug prices in Japan.
The figures underline the growing importance of overseas markets and licensing deals to Japanese pharmaceutical companies. Chugai's reliance on royalties from partnerships means its earnings can rise without a corresponding increase in manufacturing costs, a feature that has made its profit profile attractive to shareholders.
4
